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Carı´si A. Polanczyk, MD, SCD,*‡ Jorge P. Ribeiro, MD, SCD*‡
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Objectives The purpose of this study was to evaluate the efficacy of dietary intervention on blood lipids of human immuno-
deficiency virus (HIV)-1–infected patients who are started on highly active antiretroviral therapy (HAART).
Background Current guidelines recommend diet as first-step intervention for HIV-1–infected individuals with HAART-related
dyslipidemia, but there is no evidence from randomized trials to support this recommendation.
Methods Eighty-three HIV-1–infected patients, naive from HAART, were randomly assigned to HAART with dietary interven-
tion (diet group, n  43) or HAART without dietary intervention (control group, n  40) for 12 months. Diet, according
to the National Cholesterol Education Program, was given every 3 months. Before and after intervention, 24-h food
records and lipid profile were obtained. Data were analyzed by intention to treat, using mixed-effects models.
Results Diet resulted in reduction of percentage of fat intake (from 31  7% to 21  3% of calories), while controls pre-
sented no change in percentage of fat intake. Plasma cholesterol (from 151  29 mg/dl to 190  33 mg/dl) and
low-density lipoprotein cholesterol (from 85  24 mg/dl to 106  31 mg/dl) increased in the control group and were
unchanged in the diet group. Plasma triglycerides were reduced by diet (from 135  67 mg/dl to 101  42 mg/dl)
and increased in the control group (from 134  70 mg/dl to 160  76 mg/dl). After 1-year follow-up, 21% of pa-
tients who received diet had lipid profile compatible with dyslipidemia compared with 68% (p  0.001) of controls.
Conclusions Among HIV-1–positive individuals naive of previous treatment, diet prevents dyslipidemia associated with HAART.
(Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial;
NCT00429845) (J Am Coll Cardiol 2012;59:979–88) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.038The use of highly active antiretroviral therapy (HAART)
has changed the prognosis of human immunodeficiency
virus type 1 (HIV-1) infection, resulting in decreased
mortality and improved quality of life (1). However, the use
of these drugs is associated with the development of adverse
effects, such as anemia, myopathy, and lipodystrophic syn-
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accepted November 30, 2011.drome (2). Since 1998, metabolic disorders have been
described in HIV-1–infected individuals, especially in those
patients on HAART, becoming an important clinical chal-
lenge in the global management of the disease (2,3).
See page 989
Similarly, the nutritional aspects of HIV-1 infection have
changed over the last years, because the severe and poten-
tially lethal clinical problems related to progressive malnu-
trition have been replaced by subcutaneous fat atrophy,
excess of visceral fat, and metabolic disorders, often in the
context of undetectable viral load and immunological recon-
stitution. At the moment, weight gain, fat redistribution,
obesity, and dyslipidemia, characterized by hypertriglyceri-
demia and/or hypercholesterolemia, are the new nutri-
tional challenges of HIV/acquired immune deficiency
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exposed to anti–HIV-1 therapy
(4). The changes in lipid profile
can be usually detected between
the third and sixth months, but
may develop even after a year
(2,3,5,6).
Although its etiology is not
completely elucidated, several
factors may participate in the de-
velopment of the HAART-
associated dyslipidemia. Genetic
and environmental factors may
play important roles in triggering
the process, as well as the current
antiretroviral drugs and the
HIV-1 virus itself (2,3). The
AIDS Clinical Trials Group has
published guidelines for the
management of dyslipidemia in
HIV-1–infected people (3),
which are mostly based on the
recommendations of the Na-
tional Cholesterol Education
Program Adult Treatment Panel
III (NCEP ATP III) guidelines regarding the intervention
Figure 1 Study Flow Diagram
Flow of patients in the trial.
Abbreviations
and Acronyms
24 h-DR  24-h dietary
recall
AIDS  acquired immune
deficiency syndrome
BMI  body mass index
HAART  highly active
antiretroviral therapy
HDL-C  high-density
lipoprotein-cholesterol
HIV-1  human
immunodeficiency virus
type 1
LDL-C  low-density
lipoprotein-cholesterol
NNRTI  non-nucleoside
reverse transcriptase
inhibitor
PI  protease inhibitor
TC  total cholesterol
TG  triglycerides
WHR  waist-to-hip ratioin the general population (7). Because there is little infor-
mation on the efficacy and safety of pharmacological treat-
ment of HAART-associated dyslipidemia in HIV-1–
positive individuals, diet and physical exercise are
considered first-choice treatment in current guidelines (3).
n HIV-1–negative individuals, the effects of diet and
xercise on lipid profile are well documented (8,9). Al-
hough observational studies suggest that diet and exercise
nterventions are able to improve the lipid profile in HIV-
–positive patients (10,11), recent randomized clinical trials
o not corroborate these findings (12,13). Moreover, a
ecent observational study suggests that the adherence to a
editerranean diet does not influence serum lipid profiles
uring the first year of HAART (6). However, these are
hort-term studies, with reduced number of participants,
nd the use of long-term nutritional intervention in indi-
iduals who are started on HAART has not been assessed
y randomized clinical trials. Therefore, the primary aim of
his study was to assess the effects of nutritional intervention
n total cholesterol and triglyceride levels in HIV-1–infected
ndividuals who are started on HAART.
ethods
esign overview and setting. This was a randomized
linical trial conducted at a national reference center for the
o
Y
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Brazil.
Patients. From March 2004 to April 2006, HIV-1–
infected patients (diagnosed according to Centers for Dis-
ease Control revised criteria) (14), older than 17 years,
without previous antiretroviral treatment, and with indica-
tion to begin HAART were consecutively enrolled at the
HIV/AIDS outpatient clinic of the Hospital de Clı´nicas de
Porto Alegre. Pregnant women; patients with active oppor-
tunistic disease, mental impairment, or diabetes mellitus;
those being treated with drugs that cause changes in lipid
profile or illicit drugs; and those who did not accept to
participate or had logistic problems that precluded their par-
ticipation in the protocol were not included. The study
protocol was approved by the Ethics on Research Committee
of Hospital de Clı´nicas de Porto Alegre and all participants
signed an informed consent form.
Randomization and interventions. During the initial as-
sessment, all participants were instructed about nutritional
status and lifestyle, with emphasis on the benefits of having
a healthy diet and a 24-h dietary recall (24 h-DR) was used.
Next, the individuals were randomized to intervention
group or control group, on the basis of a random numbers
table, generated by allocation sequence. Both groups were
initiated on HAART therapy according to the recommen-
dations of specialized medical team and the treatment was
continued for 1 year. The intervention group received
quarterly nutritional guidance from a registered dietician
focused on dyslipidemia, based on the Phase II diet of the
NCEP ATP III guidelines (7), and were followed up to
the 12th month of treatment with antiretroviral therapy.
The control group received the same baseline nutritional
guidance, but there was no guided nutritional follow-up.
Neither group received advice on physical activity. The 24
h-DR was used in both groups at the sixth month and at the
end of the study (12th month). Lipid profile, body mass index
(BMI), and waist-to-hip ratio (WHR) were assessed in both
groups before HAART and every 3 months thereafter.
Anthropometric assessment. The waist circumference was
measured mid-way between the lowest rib margin and the
iliac crest, and the hip circumference was measured as the
widest measure over the buttocks. The height and weight
were measured using a mechanical anthropometric scale.
BMI was calculated by dividing the weight by the square
height (BMI  weight (kg) / [height(cm)]2). All anthro-
pometric measures were obtained by an investigator
(R.K.L.) who was unaware of patient allocation.
Dietary assessment and intervention. Diet programs were
planned individually, on the basis of nutritional needs,
socioeconomic status, and the dietary habits of each person.
Diets were designed according to a total amount of calories
in order to maintain or reduce weight, as needed, with 25%
of the total calories in lipids (5% saturated fatty acids, 10%
monounsaturated, and 10% polyunsaturated), 15% in pro-
teins (50% high biologic value), and 60% in carbohydrates,
including 30 g per day of fiber and 200 mg of dietary
scholesterol. In addition, the volunteers were instructed not
to eat anything containing trans fatty acids (9). The diet
plan included a detailed description of the types of foods per
group, with possible replacements, times, and daily amounts
in home measures, besides a list of not-allowed types of
foods. Regarding dietary counseling, patients received in-
structions about the selection and amounts of foods, as well
as cooking techniques. The directions were provided after
dietary history and were mainly composed of information on
the adjustment of total fat intake, reduction of saturated fat,
cholesterol, and trans fatty acids, as well as increase of fibers,
especially of the soluble type. Information on food intake
was obtained using the 24 h-DR method, through which
the individuals provided detailed reports on food and
beverages consumed during the 24 h before the interview.
Questions were asked about amounts and home-measured
portion sizes. In order to increase the reliability of the
measurements reported, a manual of photographic record
for dietary inquiries was used as a support material (15).
Home measures were converted into grams and milliliters for
quantitative analysis of the consumed energy and nutrients
Baseline Characteristics of the PatientsTable 1 Baseline Characteristics of the Patients
Diet
(n  43)
Control
(n  40) p Value
Male 17 (39.5) 14 (35.0) 0.842*
Age, yrs 38 11 37 10 0.668†
Smoking 12 (28) 10 (25) 0.959*
Body mass index, kg/m2 24 3.4 23 3.2 0.620†
Waist-to-hip ratio, cm 0.86 0.06 0.86 0.05 0.900†
Medication exposure
AZT  3TC  EFV 33 (76.7) 34 (85.0) 0.683‡
AZT  3TC  LPV/r 2 (4.7) 3 (7.5)
AZT  3TC  ATZ 4 (9.3) 2 (5.0)
AZT  3TC  ATZ/r 2 (4.7) 1 (2.5)
AZT  3TC  IDV/r 1 (2.3) 0
d4T  3TC  EFV 1 (2.3) 0
CD4 173 100 181 121 0.749†
Lipids
Total cholesterol, mg/dl 153 36 151 29 0.735†
HDL-C, mg/dl 40 16 39 17 0.709†
LDL-C, mg/dl 85 26 85 24 0.933†
Triglycerides, mg/dl 135 67 134 70 0.921†
Nutrients diet
Caloric intake, kcal/day 2,662 614 2,594 550 0.594†
Carbohydrate, % 52 7 51 6 0.402†
Protein, % 16 4 16 3 0.882†
Total fat, % 31 7 32 5 0.445†
Saturated fat acids, % 12 4 12 3 0.623†
Monounsaturated fat acids, % 11 3 12 3 0.109†
Polyunsaturated fat acids, % 5 2 5 2 0.702†
Cholesterol, mg/day 406 156 366 153 0.233†
Fiber, g/day 19 6 19 7 0.642†
Values are n (%) or mean  SD. *Value obtained by chi-square test with Yates correction. †Value
btained by Student t test for independent samples. ‡Value obtained by chi-square test without
ates correction.
3TC  lamivudine; ATZ  atazanavir; ATZ/r  atazanavir/ritonavir; AZT  zidovudine; d4T tavudine; EFV  efavirenz; HDL-C  high-density lipoprotein cholesterol; IDV/r  indinavir/
ritonavir; LDL-C  low-density lipoprotein cholesterol; LPV/r  lopinavir/ritonavir.
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Health Informatics Center of Escola Paulista de Medicina
(São Paulo, Brazil). Food and preparations that were apart
from the list provided by the program were included through
complementary tables (16,17), or nutritional information on
the labels of the manufactured products. In addition, the total
calories, carbohydrates, proteins, lipids, fibers, cholesterol, sat-
urated fatty acids, and monounsaturated and polyunsaturated
acids were selected for analysis according to the recommenda-
tions of the guidelines of the NCEP ATP III (7) and of the
AIDS Clinical Trials Group (2).
Lipid profile. Lipid profile included measurements of total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), triglycerides (TG), and low-density lipoprotein
cholesterol (LDL-C) after a 12-h fast. TC and TG levels
were measured with colorimetric enzymatic methods and
HDL-C was measured by the homogeneous colorimetric
enzymatic method (Hitachi 917, Roche Diagnostics
GmbH, Mannheim, Germany). LDL-C was calculated
using the Friedewald Formula if TG levels were 400
mg/dl (18). Dyslipidemia was defined as plasma levels of
fasting TG 150 mg/dl and/or fasting total TC 200
mg/dl and/or LDL-C 130 mg/dl (9).
Statistical analysis. Initially, a sample size was estimated
in 88 individuals for each group, considering an increase of
20% in the TG levels without nutritional intervention in
persons who start HAART (19), with a statistical power of
80% for an   5%. A planned interim analysis was
erformed when 60 patients had concluded 6 months of
ollow-up, for reassessment of the statistical power. In this
nterim analysis, it was found that a sample size of 26
ndividuals in each group would have enough power to
etect a clinically significant effect of the intervention.
herefore, recruitment was stopped. Data were analyzed on
Characterization of the HAARTTable 2 Characterization of the HAART
HAART
Baseline
Diet
(n  43)
Control
(n  40) p Value
Di
(n 
AZT  3TC  EFV 33 (76.7) 34 (85.0)
0.683
30 (6
AZT  3TC  LPV/r 2 (4.7) 3 (7.5) 3 (7
AZT  3TC  ATZ 4 (9.3) 2 (5.0) 4 (9
AZT  3TC  ATZ/r 2 (4.7) 1 (2.5) 3 (7
AZT  3TC  IDV/r 1 (2.3) 0 1 (2
d4T  3TC  EFV 1 (2.3) 0 2 (4
2 NRTI  1 NNRTI 34 (79.0) 34 (85.0) 32 (7
2 NRTI  1 PI 4 (9.3) 3 (7.5) 4 (9
2 NRTI  1 PI/r 5 (11.6) 3 (7.5) 7 (1
Diet
2 AZT  3TC  EFV ) 2 d4T  3TC  EFV
1 AZT  3TC  EFV ) 1 AZT  3TC  ATZ/r
1 AZT  3TC  EFV ) 1 AZT  3TC  LPV/r
1 d4T  3TC  EFV ) 1 AZT  3TC  EFV
Values are n (%).
HAART  highly active antiretroviral therapy; NNRTI  non-nucleoside reverse transcriptase inhibito
inhibitor/ritonavir; other abbreviations as in Table 1.he Statistical Package for Social Sciences (version 16.0,
PSS, Chicago, Illinois). Continuous variables are ex-
ressed as mean  SD and categorical variables are ex-
ressed as proportions. After randomization, groups were
ompared by means of the Student t test for continuous
ariables and the chi-square or the Fisher exact tests for
ategorical variables. The measurements taken at different time
ntervals were compared by linear mixed models (20), which
ere fitted considering metabolic and lipid parameters as
ependent variables to evaluate the effect of group allocation,
djusting for time effect (interaction term of time · group). All
nalyses were performed by intention to treat, and a p value
0.05 was considered statistically significant.
esults
atients. Of the 105 screened individuals, 90 (86%) were
onsidered eligible and were included in the study, but 7
ere excluded from the final analysis due to nonadherence
o HAART, confirmed by a viral load 5 copies/ml (5 in
he control group) (Fig. 1). All 83 individuals reached the sixth
onth of the study. After this period, 1 woman in the interven-
ion group became pregnant, and 2 individuals were excluded
rom the control group (1 death from cranial fracture due to
eizures and 1 loss to follow-up). Statins were prescribed to 2
ndividuals in this period in the control group.
aseline characteristics and pharmacologic treatment.
able 1 shows the demographic, anthropometric, and bio-
hemical characteristics, as well as the food intake and
AART prescribed at baseline. The groups presented
imilar characteristics, with predominance of women. Ther-
peutic regimens consisted of 2 nucleoside analog reverse
ranscriptase inhibitors plus 1 protease inhibitor (PI), with
r without low-dose ritonavir (19%) or non-nucleoside
6 Months 12 Months
Control
(n  40) p Value
Diet
(n  43)
Control
(n  38) p Value
31 (77.5)
0.896
30 (69.8) 29 (76.3)
0.919
2 (5.0) 3 (7) 2 (5.3)
4 (10.0) 4 (9.3) 4 (10.5)
2 (5.0) 3 (7.0) 2 (5.3)
0 1 (2.3) 0 (0.0)
1 (2.5) 2 (4.7) 1 (2.6)
32 (80.0) 32 (74.4) 30 (78.9)
4 (10.0) 4 (9.3) 4 (10.5)
4 (10.0) 7 (16.3) 4 (10.5)
Control
2 AZT  3TC  EFV ) 2 AZT  3TC  ATZ
1 AZT  3TC  EFV ) 1 d4T  3TC  EFV
1 AZT  3TC  LPV/r ) 1 AZT  3TC  ATZ/ret
43)
8.9)
.0)
.3)
.0)
.3)
.7)
4.4)
.30)
6.3)r; NRTI  nucleoside reverse transcriptase inhibitor; PI  protease inhibitor; PI/r  protease
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to Brazilian guidelines (21). The most commonly prescribed
HAART regimen was the combination of zidovudine,
lamivudine, and efavirenz. During the study, 9 individuals
needed to switch therapy due to toxicity (5 on intervention
group). However, all antiretroviral changes occurred in the
first 3 months of the study (diet: 66  33 days; control:
67  29 days) and were not related to dyslipidemia (Table 2).
Dietary assessment. Table 3 shows the estimate of the
usual intake of calories and macronutrients that was re-
ported in the 24 h-DR at baseline, at 6 months and at 12
months of the study. The nutritional intervention resulted
in the reduction of total calories, cholesterol, and percentage
of lipid and saturated fatty acid intake, as well as increased
percentage of carbohydrate and fiber consumption. The
Estimate of the Food Intake of the 24 h Record at Baseline, 6 MonTable 3 Estimate of the Food Intake of the 24 h Record at Bas
Group
Diet Cont
Caloric intake, kcal
Baseline 2,662 614 (43) 2,594 5
6 months 2,193 519 (43) 2,738 8
12 months 2,281 512 (43) 2,806 6
Carbohydrate, %
Baseline 52 7 (43) 51 6
6 months 61 3 (43) 54 6
12 months 63 3 (43) 51 6
Protein, %
Baseline 16 4 (43) 16 3
6 months 15 3 (43) 16 7
12 months 16 3 (43) 17 6
Total fat, %
Baseline 31 7 (43) 32 5
6 months 24 4 (43) 31 5
12 months 21 3 (43) 31 6
SFA, %
Baseline 12 4 (43) 12 3
6 months 6 2 (43) 11 3
12 months 6 1 (43) 11 3
MFA, %
Baseline 11 3 (43) 12 3
6 months 9 2 (43) 12 3
12 months 8 1 (43) 12 3
PSA, %
Baseline 5 2 (43) 5 2
6 months 6 2 (43) 5 2
12 months 5 1 (43) 5 2
Cholesterol, mg
Baseline 406 156 (43) 366 1
6 months 135 68 (43) 352 1
12 months 144 65 (43) 395 1
Fiber, g
Baseline 19 6 (43) 19 7
6 months 29 9 (43) 21 7
12 months 33 10 (43) 22 8
Values are mean  SD (n). *p Values obtained by linear mixed models.
MFA  monounsaturated fatty acids; PFA  polyunsaturated fatty acids; SFA  saturated fatty acids.percentage of protein and polyunsaturated fatty acids re-
mained stable throughout the study in both groups. How-
ever, there was a significant reduction in the percentage of
monounsaturated fatty acid intake in the group that received
nutritional intervention.
Anthropometric assessment. Table 4 shows the results on
anthropometric measures. BMI remained stable in the
intervention group, while in the control group there was a
significant increase after 12 months of nutritional follow-up
(p  0.001) (Fig. 2A). The WHR presented a slight
increase in both groups, with a significantly smaller incre-
ment in the diet group.
Lipid profile. The results of lipid profile are shown on
Table 3 and Figure 2. The nutritional follow-up maintained
TC plasma levels (Fig. 2B) and LDL-C levels (Fig. 2C)
and 12 Months, 6 Months, and 12 Months
p Value*
Group Time Interaction
)
0.006 0.005 0.001)
)
0.001 0.001 0.001
0.300 0.809 0.774
0.001 0.001 0.001
0.001 0.001 0.001
0.001 0.001 0.001
0.180 0.096 0.051
)
0.001 0.001 0.001)
)
0.001 0.001 0.001ths,eline
rol
50 (40
06 (40
53 (38
(40)
(40)
(38)
(40)
(40)
(38)
(40)
(40)
(38)
(40)
(40)
(38)
(40)
(40)
(38)
(40)
(40)
(38)
53 (40
63 (40
85 (38
(40)
(40)
(38)
i
a
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The Diet HIV Trial March 13, 2012:979–88stable in the intervention group, with significant increments
in the control group (p 0.001). TG levels decreased in the
intervention group, while in the control group these levels
had a significant increase (p  0.001) (Fig. 2D). After 6
months, TC, LDL-C, and TG levels were significantly
different between diet and control group, after adjustment
for time effect (interaction term p  0.001). There was a
similar increase in HDL-C in both groups throughout the
study.
At the end of the 1-year period, hypercholesterolemia
was diagnosed in 14 (39%) individuals in the control group
and only in 3 (7%) in the intervention group (p0.001).
Hypertriglyceridemia was found in 20 (51%) and in 7 (16%)
individuals, respectively (p  0.001). Overall, 9 (21%)
ndividuals who received nutritional intervention developed
Measures of the Lipid Profile, BMI, and WHR at Baseline, 6 MonthTable 4 Measures of the Lipid Profile, BMI, and WHR at Baseli
Group
Diet Co
Total cholesterol, mg/dl
Baseline 153 36 (43) 151
3 months 172 28 (43) 172
6 months 162 21 (43) 184
9 months 162 20 (43) 180
12 months 161 22 (43) 190
HDL-C, mg/dl
Baseline 40 16 (43) 39
3 months 49 12 (43) 49
6 months 54 14 (43) 52
9 months 58 13 (43) 50
12 months 59 17 (43) 54
LDL-C, mg/dl
Baseline 85 26 (43) 85
3 months 97 26 (43) 95
6 months 86 21 (43) 99
9 months 83 18 (43) 101
12 months 81 23 (43) 106
Triglycerides, mg/dl
Baseline 135 67 (43) 134
3 months 132 58 (43) 141
6 months 106 42 (43) 175
9 months 106 48 (43) 150
12 months 101 42 (43) 160
BMI, kg/m2
Baseline 23.5 3.4 (43) 23.2
3 months 24.1 3.4 (43) 23.7
6 months 24.0 3.6 (43) 24.8
9 months 24.3 3.4 (43) 25.8
12 months 24.2 3.3 (43) 26.2
WHR, cm
Baseline 0.86 0.06 (43) 0.86
3 months 0.87 0.06 (43) 0.87
6 months 0.87 0.06 (43) 0.88
9 months 0.88 0.06 (42) 0.90
12 months 0.89 0.06 (42) 0.91
Values are mean  SD (n). *p Values obtained by linear mixed models.
BMI  body mass index; HDL-C  high-density lipoprotein-cholesterol; LDL-C  low-density lipolterations in lipid profile compatible with dyslipidemia,compared with 26 (68%) in the control group (p  0.001)
(Table 5).
Discussion
In this 1-year randomized trial, we demonstrate, for the first
time, that a diet based on the NCEP ATP III guidelines (7)
was able to prevent dyslipidemia induced by HAART in
patients who were previously naive to these medications.
The nutritional guidelines used in this study focused on the
quality of the lipids consumed, with the purpose of reducing
the saturated and trans fats and increasing monounsaturated
and polyunsaturated fatty acids and fibers, as well as
decreasing daily cholesterol intake. Our study demonstrates
d 12 MonthsMonths, and 12 Months
p Value
Group Time Interaction
0)
0.007 0.001 0.001
0)
0)
7)
8)
0)
0.199 0.001 0.126
0)
0)
7)
8)
0)
0.006 0.003 0.001
0)
7)
7)
8)
0)
0.002 0.833 0.001
0)
40)
7)
8)
0)
0.385 0.001 0.001
0)
0)
7)
8)
(40)
0.245 0.001 0.049
(40)
(40)
(37)
(38)
-cholesterol; WHR  waist-to-hip ratio.s, anne, 6
ntrol
29 (4
28 (4
36 (4
33 (3
33 (3
17 (4
15 (4
18 (4
16 (3
19 (3
24 (4
23 (4
27 (3
25 (3
31 (3
70 (4
64 (4
125 (
80 (3
76 (3
3.2 (4
3.4 (4
3.5 (4
3.6 (3
4.1 (3
0.05
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0.06that this nutritional intervention controlled the changes in
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March 13, 2012:979–88 The Diet HIV Triallipid profile in HIV-1–infected individuals who started
HAART. In the group that received dietary intervention,
mean plasma levels of total cholesterol, triglycerides,
LDL-C, and BMI remained stable during the 12-month
follow-up, while the control group presented the expected
increment.
Our findings also confirm that individuals who start
HAART are at risk to develop dyslipidemia (almost 70% in
the control group of our study) according to revised NCEP
ATP III criteria (even with initial dietary guidance) (7), and
it could be avoided by the beneficial effects of nutritional
intervention as done in our study. Fitch et al. (13) random-
ized a small group HIV-1–infected individuals with meta-
bolic syndrome to an intensive lifestyle modification pro-
gram, which included dietary intervention, or to a control
group. After 6 months, despite improvement in anthropo-
metric variables, blood pressure, and physical activity, lipid
profile was not improved by the lifestyle modification
program. Our group has also failed to demonstrate the effect
of exercise training on the lipid profile of HIV-1–infected
individuals (12). Both of these trials (12,13) evaluated
patients on chronic HAART, while in the present study
only patients naive from HAART were included. These
Figure 2 Effects on Body Mass Index and Blood Lipids
Effect of the nutritional intervention during 12 months on the body mass index (A)
and triglycerides (D). Values are mean  SD.findings raise the hypothesis that, for a dietary intervention sto be effective in controlling dyslipidemia in HIV-1–
infected individuals, it should be started early.
Our findings are consistent with previous uncontrolled
studies. Barrios and coworkers (22) found a significant
reduction in TC and TG in a large cohort of patients who
had good compliance to a low-fat diet for 6 months. In the
retrospective analysis of Batterham and coworkers (10),
here were also significant reductions in TC and TG after
hanges in the diet. In the present study, the dietary
ntervention was also able to prevent the increase in LDL-C
ssociated with HAART, probably due to the reduced
ntake of saturated fatty acids and cholesterol. In isoener-
etic conditions, it is expected that 1% reduction in satu-
ated fat intake and 100 mg/day of cholesterol may cause a
eduction of 1 to 3% in LDL-C levels (23). The present
tudy is the first randomized, controlled trial to isolate the
ffects of dietary intervention in HIV-1–infected individuals
ho are started on HAART. Previous controlled trials
valuated the effects of diet associated with other interven-
ions, including physical activity (11,12), and the use of
rugs such as statins (24) and fibrates (25) or supplemen-
ation with fatty acids (26).
In the present study, both groups had significant and
cholesterol levels (B), low-density lipoprotein cholesterol (LDL-C) (C),, totalimilar increments in HDL-C with HAART. Studies
chi-square test with Yates correction.
HDL-C  high-density lipoprotein-cholesterol; LDL-C  low-density lipoprotein-cholesterol.
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with low HDL-C levels (27). More advanced stages of
HIV-1 infection and lower CD4 lymphocyte count have
been associated with lower HDL-C levels (28), and it has
been shown that HDL-C levels may remain low despite
HAART (29). It has also been shown that when NNRTI
are used in the beginning of the therapy or as a replacement
for a PI, they can increase the HDL-C levels (13% and 27%,
respectively) (30,31). Therefore, it is possible that the
viremic control induced by HAART, as well as the frequent
use of efavirenz, might have contributed to the increase in
HDL-C levels in both groups.
Our patients presented mean BMI and WHR within the
limits of normality at baseline. It is well known that patients
who are started on HAART may present body changes such
as accumulation (lipohypertrophy) and/or with loss (lipoa-
trophy) in body fat (32) and previous cohort studies in the
HAART era have consistently found an increase in body
weight after the diagnosis of HIV (33), but the mechanisms
responsible for the change have not been elucidated (32).
After 1 year, the dietary intervention prevented some of the
anthropometric changes associated with the lipodystrophic
syndrome, by preventing part of the weight gain and fat
redistribution. This was most likely related to the reduction
in caloric intake in the group who followed the diet, while
the control group increased the caloric intake (Table 3).
Therefore, our findings support the hypothesis that these
patients may gain more weight in an attempt to obscure
their diagnosis (33). Currently, there is no consensus on
which is the method that better reflects the real food intake
of humans (34). Despite the known limitations of the 24
h-DR (34), it was sensitive enough to detect the effects of
our dietary intervention and can be easily reproduced in
other clinical settings.
Several theories have been proposed to explain the asso-
ciation between HAART and dyslipidemia, although none
of them explains all aspects (32). It is important to notice
that some drugs are more likely to produce lipid changes,
mainly stavudine (nucleoside reverse transcriptase inhibi-
tor), efavirenz (NNRTI), and PIs (with the possible excep-
tion of atazanavir, which is the PI less associated to
dyslipidemia) (35,36). Nevertheless, as shown in Table 2,
the groups were comparable regarding HAART regimen.
Overall, 23% of the individuals were using 1 PI in their
regimen; however, 10% were on atazanavir as a part of
HAART, which is known to be less associated with the
development of dyslipidemia (35,36).
Strengths and weaknesses of the study. Strengths of this
study include its randomized design, its intention-to-treat
analysis, a high compliance to the intervention, and the
large number of women included. Because we have previ-
ously shown that aerobic exercise training had no significant
effect on blood lipids in HIV-1–positive individuals on
HAART (14), the present trial was focused on the isolated
effects of dietary intervention. Therefore, our findings doOutcomes of the Lipid Profile Before,D ring, and Aft r the Nutritional InterventionTable 5 Outcom s of th Lipid Profile Before,During, and After the Nutritional Intervention
Group
p ValueDiet Control
Total cholesterol, mg/dl
Baseline 153 36 (43) 151 29 (40)
200 38 (88.4) 39 (97.5)
0.203*
200 5 (11.6) 1 (2.5)
6 months 162 21 (43) 184 37 (40)
200 42 (97.7) 28 (70.0)
0.002†
200 1 (2.3) 12 (30.0)
12 months 161 22 (43) 190 33 (38)
200 40 (93.0) 22 (61.1)
0.001†
200 3 (7.0) 14 (38.9)
HDL-C, mg/dl
Baseline 40 16 (43) 39 17 (40)
40 20 (46.5) 26 (65)
0.141†
40 23 (53.5) 14 (35)
6 months 54 14 (43) 52 18 (40)
40 4 (9.3) 8 (20.0)
0.284†
40 39 (90.7) 32 (80.0)
12 months 59 17 (43) 54 19 (38)
40 4 (9.3) 10 (26.3)
0.084†
40 39 (90.7) 28 (73.7)
LDL-C, mg/dl
Basal 85 26 (43) 85 24 (40)
130 41 (97.7) 38 (95.0)
0.607*
130 1 (2.3) 2 (5.0)
6 months 86 21 (43) 99 27 (37)
130 42 (97.7) 31 (83.8)
0.045*
130 1 (2.3) 6 (16.2)
12 months 81 23 (43) 106 31 (38)
130 42 (97.7) 31 (81.6)
0.023*
130 1 (2.3) 7 (18.4)
Triglycerides, mg/dl
Baseline 135 67 (43) 134 70 (40)
150 28 (65.1) 28 (70.0)
0.810†
150 15 (34.9) 12 (30.0)
6 months 106 42 (43) 175 125 (40)
150 36 (83.7) 22 (55.0)
0.009†
150 7 (16.3) 18 (45.0)
12 months 101 42 (43) 160 76 (38)
150 36 (83.7) 18 (47.4)
0.001†
150 7 (16.3) 20 (52.6)
Dyslipidemia
Baseline
Yes 18 (41.9) 13 (32.5)
0.513†
No 25 (58.1) 27 (67.5)
6 months
Yes 8 (18.6) 16 (40.0) 0.001†
No 35 (81.4) 24 (60.0)
12 months
Yes 9 (20.9) 26 (68.4)
0.001†
No 34 (79.1) 12 (31.6)
Values are mean  SD (n) or n (%). *Value obtained by the Fisher test. †Value obtained bynot exclude the possibility that a more complete lifestyle
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advice on physical activity was given to the patients and we
also did not evaluate physical activity during the trial.
However, the possibility of cointervention, with increase in
physical activity in the group that received dietary advice, is
unlikely. The focus on HIV-1–infected patients who were
naive of HAART allowed us to demonstrate a clear effect of
dietary intervention in preventing dyslipidemia in this set-
ting; however, it left unanswered the question of whether
the same intervention can revert dyslipidemia in patients
who are already taking HAART, and this should be
addressed by future controlled trials. Likewise, the 1-year
follow-up in a cohort of HIV-1–infected individuals who
are at low risk for cardiovascular events cannot ascertain if
the control of dyslipidemia might have any impact in prog-
nosis. However, if we use the results of the meta-analysis
involving more than 90,000 HIV-negative individuals (37),
which showed that for each 39 mg/dl reduction in LDL-C
levels there is a 23% reduction in the rate of cardiovascular
events, we could estimate a potential reduction of 15% in the
rate of cardiovascular events in our HIV-1–infected patients
with the use of dietary intervention.
Conclusions and Policy Implications
Our study showed the efficacy of nutritional intervention in
the prevention of changes in lipid profile of HIV-positive
individuals who start HAART. These findings indicate that
nutritional intervention should be considered for all patients
who start HAART. Future studies should be conducted to
evaluate the impact of this intervention on clinical outcomes
associated with lipid profile.
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